



**HESTER**

**Hester Biosciences Limited**

**Head Office**

Pushpak, 1st Floor  
Panchvati Circle  
Motilal Hirabhai Road  
Ahmedabad 380006  
Gujarat, India  
**Phone** +91 79 26445106

**Factory**

Village Merda-Ardraj  
Taluka Kadi  
District Mehsana  
Gujarat 382721, India  
**Phone** +91 2764 285 502  
+91 2764 285 453

**Email** mail@hester.in  
**Toll Free** 1 800 233 7937  
[www.hester.in](http://www.hester.in)

**CIN** L99999GJ1987PLC022333

**30 January 2024**

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

**Scrip Code: 524669**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai 400 051

**Symbol: HESTERBIO**

**Dear Sir/ Madam:**

**Subject: Disclosure under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Pursuant to Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (as amended from time to time), we hereby submit that Oaklane Capital Management LLP, along with persons acting in concert, has acquired 10,000 equity shares of the Company on 29 January 2024. This acquisition has resulted in crossing the five percent limit, as stipulated by Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and triggered the disclosure requirements.

A disclosure dated 30 January 2024 under Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 enclosed herewith.

You are requested to take the above information on your record.

**Sincerely**  
**For Hester Biosciences Limited**

Vinod  
Mali

Digitally signed  
by Vinod Mali  
Date:  
2024.01.30  
15:59:14 +05'30'

**Vinod Mali**  
**Company Secretary & Compliance Officer**

Enclosure: As above

Date: January 30, 2024

To,  
**Hester Biosciences Limited**  
Pushpak, 1<sup>st</sup> Floor, Panchvati Circle,  
Motilal Hirabhai Road, Ahmedabad,  
Gujarat – 380006  
[cs@hester.in](mailto:cs@hester.in) / [mail@hester.in](mailto:mail@hester.in)

**Subject: Disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.**

Dear Sir / Madam,

We, Oaklane Capital Management LLP, are a registered portfolio manager with the Securities and Exchange Board of India (**SEBI**). We are making this disclosure to you, in the prescribed format (*annexed to this letter*) in terms of the provisions of regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

We trust this meets your requirements.

Sincerely,

**For Oaklane Capital Management LLP**

  
\_\_\_\_\_  
Ashwini Desai  
Principal Officer



**Encl:** as above

**Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

<b>Part-A- Details of the Acquisition</b>			
Name of the Target Company (TC)	Hester Biosciences Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Oaklane Capital Management LLP (Portfolio Manager) and its clients. SEBI Registration Number INP000006624.		
Whether the acquirer belongs to Promoter/Promoter group	No.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited 3. Metropolitan Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t total share/ voting capital wherever applicable(*)	% w.r.t. total diluted share/ voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer alongwith PAC of:</b>			
(a) Shares carrying voting rights	4,20,203	4.94%	4.94%
(b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	0%	0
(c) Voting rights (VR) otherwise than by equity shares	-	0%	0
(d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	-	0%	0
<b>(e) Total (a+b+c+d)</b>	<b>4,20,203</b>	<b>4.94%</b>	<b>4.94%</b>
<b>Details of acquisition</b>			
(a) Shares carrying voting rights acquired	10,000	0.12%	0.12%
(b) VRs acquired otherwise than by equity shares	-	-	-
(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	-	-	-
(d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
<b>(e) Total (a+b+c+/-d)</b>	<b>10,000</b>	<b>0.12%</b>	<b>0.12%</b>
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
(a) Shares carrying voting rights	4,30,203	5.06%	5.06%
(b) VRs otherwise than by equity shares	-	-	-
(c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
(d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	-	-	-
<b>(e) Total (a+b+c+d)</b>	<b>4,30,203</b>	<b>5.06%</b>	<b>5.06%</b>

Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Shares are acquired through open market transaction(s) through stock exchange.
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	29th January 2024
Equity share capital / total voting capital of the TC before the said acquisition	85,06,865
Equity share capital/ total voting capital of the TC after the said acquisition	85,06,865
Total diluted share/voting capital of the TC after the said acquisition	85,06,865